Clinician Articles
Vayarin for ADHD no longer sold in the U.S.
This month Enzymotec, the makers of Vayarin, quietly announced on their website that they would no longer sell its product in the U.S. This leaves patients who have been taking it in a quandary without support. While the company’s announcement cites “a lack of alignment with our business strategy” as an explanation, no one gives […]
The Adult ADHD Quality Measures Initiative
Faraone SV, Silverstein MJ, Antshel K, Biederman J, Goodman DW, Mason O, Nierenberg AA, Rostain A, Stein MA, Adler LA. J of Attention Disorder 2018:1-16 click to read abstract
So you can’t get your ADHD medication approved by insurance? Part 2
This is Part 2 to a previous blog: This brings us to the next objection insurance companies will raise – the issue of safety. In citing safety as a reason for the denial of daily stimulant doses that exceed FDA daily max allowances, they deliberately and knowingly misrepresent the meaning of FDA max daily dose. […]
Dr. David W. Goodman Interview by NPR Morning Edition May 29, 2017
National Public Radio recently posted my interview (click on “Heard on Morning Editon”) from April 2017 about a research publication reviewing a revised adult ADHD screener developed in coordination with the World Health Organization. What the journalist didn’t know at the time that I will share with you is that I was a pre-publication peer reviewer […]
American Professional Society for ADHD and Related Disorders 2016 conference speaker videos
American Professional Society for ADHD and Related Disorders has posted videos by many of the speakers at this year’s conference. For those professionals and others who are interested in the covered topics, we can listen the 5 min videos descriptions by the speakers of their topics. My video about ADHD in older adults is included. […]
ADHD in older adults: First published review of world-wide literature
On December 16, 2015, our article reviewing the world’s English scientific literature on ADHD in adults over age 50 years was published online in Drugs and Aging, an international journal. While there is a paucity of research, there are enough publications to merit pulling this literature together into one paper. Most of research comes out […]
FDA improves Drug Labeling for Pregnancy and Lactation
Over the years, it has been challenging for psychiatrists to manage the risks of psychiatric medications in patients who considered childbearing, become pregnant, and chose to breastfeed. And while there is some information on many psychiatric medications, there remains little in regards to stimulant medications. Unfortunately, there is no registry for stimulant exposed pregnancy by […]
SavRx disrupts effective ADHD treatment
With an increasing number of adults being nearly diagnosed with ADHD, the expense of ADHD medications for insurance companies has escalated. While the annual prescription increase for childhood ADHD is less than 3%, the ADHD prescription market is growing at approximately 10% per year. As a result of this change, companies are under increased pressure […]
ADD stimulant substitution by insurance prohibited in Maryland
Step therapy is the requirement that a patient first try less costly medication before being prescribed medication a doctor thinks is best for the individual patient and specific symptoms/history. In the recent past, insurance companies had requested that adults with ADHD first be treated with a short-acting stimulant despite the fact that no short-acting stimulant […]
Burnout: Control out of Chaos in the age of COVID
When a pattern is not seen, then chaos is perceived. I was invited by PeerVoice, an international medical newsletter from Luxembourg, to write about the psychological pattern of adaptation to crisis and perceived chaos. While the duration of psychological stages may be different amongst individuals, there is a predictable pattern of psychological reaction to crises. […]